Romiplostim 250 µg [clinicaltrials_resource:NCT00413283/group/E2]
Participants received romiplostim 250 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
Hyperlipidaemia for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/100/count/398]Hypoglycaemia for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/101/count/402]Hypokalaemia for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/102/count/406]Hypomagnesaemia for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/103/count/410]Hyponatraemia for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/104/count/414]Arthralgia for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/105/count/418]Back pain for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/106/count/422]Bone pain for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/107/count/426]Joint swelling for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/108/count/430]Muscle fatigue for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/109/count/434]Muscular weakness for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/110/count/438]Musculoskeletal chest pain for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/111/count/442]Musculoskeletal pain for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/112/count/446]Myalgia for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/113/count/450]Pain in extremity for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/114/count/454]Cancer pain for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/115/count/458]Amnesia for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/116/count/462]Burning sensation for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/117/count/466]Dizziness for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/118/count/470]Headache for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/119/count/474]Hypoaesthesia for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/120/count/478]Neuropathy peripheral for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/121/count/482]Paraesthesia for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/122/count/486]Syncope for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/123/count/490]Tremor for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/124/count/494]Confusional state for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/125/count/498]Depression for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/126/count/502]Insomnia for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/127/count/506]Restlessness for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/128/count/510]Haematuria for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/129/count/514]Nocturia for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/130/count/518]Renal failure for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/131/count/522]Renal pain for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/132/count/526]Urinary incontinence for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/133/count/530]Chronic obstructive pulmonary disease for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/134/count/534]Cough for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/135/count/538]Dyspnoea for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/136/count/542]Epistaxis for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/137/count/546]Haemoptysis for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/138/count/550]Pleural effusion for NCT00413283 for E2 in NCT00413283 [clinicaltrials_resource:NCT00413283/other_events/139/count/554]
group [clinicaltrials_vocabulary:group]
Romiplostim 250 µg [clinicaltrials_resource:NCT00413283/group/E2]
Participants received romiplostim 250 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
Bio2RDF identifier
NCT00413283/group/E2
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT00413283/group/E2
group id [clinicaltrials_vocabulary:group-id]
description
Participants received romiplos ...... andard institutional practice.
@en
identifier
clinicaltrials_resource:NCT00413283/group/E2
title
Romiplostim 250 µg
@en
type
label
Romiplostim 250 µg [clinicaltrials_resource:NCT00413283/group/E2]
@en